Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

A trio of mRNA molecules could help guard against the harmful effects of aging on immune cells, a study in mice finds. A new ...

MIT researchers have developed an experimental mRNA-based therapy that restored key immune functions lost with age in mice.

The study examined 180 patients with advanced lung cancer who received a COVID vaccine within 100 days before or after beginning immunotherapy, as well as 704 similar patients who did not. Vaccinated ...

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and ...

Researchers at Penn Medicine have developed an mRNA vaccine that could potentially cure allergies by stopping allergens from ...